MTNB vs. AFMD, RLYB, RLMD, PHXM, IXHL, GOVX, NXTC, DWTX, HOTH, and TRIB
Should you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Affimed (AFMD), Rallybio (RLYB), Relmada Therapeutics (RLMD), PHAXIAM Therapeutics (PHXM), Incannex Healthcare (IXHL), GeoVax Labs (GOVX), NextCure (NXTC), Dogwood Therapeutics (DWTX), Hoth Therapeutics (HOTH), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry.
Matinas Biopharma vs.
Affimed (NASDAQ:AFMD) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.
30.8% of Affimed shares are held by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 6.0% of Matinas Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Matinas Biopharma has higher revenue and earnings than Affimed.
In the previous week, Affimed had 12 more articles in the media than Matinas Biopharma. MarketBeat recorded 13 mentions for Affimed and 1 mentions for Matinas Biopharma. Affimed's average media sentiment score of 0.44 beat Matinas Biopharma's score of 0.00 indicating that Affimed is being referred to more favorably in the media.
Affimed has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
Affimed presently has a consensus target price of $13.50, suggesting a potential upside of 1,416.85%. Given Affimed's stronger consensus rating and higher possible upside, research analysts plainly believe Affimed is more favorable than Matinas Biopharma.
Affimed received 439 more outperform votes than Matinas Biopharma when rated by MarketBeat users.
Matinas Biopharma has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Matinas Biopharma's return on equity of -123.06% beat Affimed's return on equity.
Summary
Affimed beats Matinas Biopharma on 9 of the 15 factors compared between the two stocks.
Get Matinas Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Matinas Biopharma Competitors List
Related Companies and Tools
This page (NYSE:MTNB) was last updated on 4/24/2025 by MarketBeat.com Staff
Buy MTNB Stock Free MTNB Stock Alerts